Anzeige
Mehr »
Samstag, 28.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A4004R | ISIN: US5907174016 | Ticker-Symbol: LWB1
Siehe auch MESOBLAST LIMITED
Frankfurt
27.06.25 | 15:29
9,150 Euro
+2,23 % +0,200
1-Jahres-Chart
MESOBLAST LIMITED ADR Chart 1 Jahr
5-Tage-Chart
MESOBLAST LIMITED ADR 5-Tage-Chart

Aktuelle News zur MESOBLAST LIMITED ADR Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiMESOBLAST LIMITED: Ceasing to be a substantial holder-
17.06.MESOBLAST LIMITED: Ceasing to be a substantial holder-
17.06.Why is the Mesoblast share price up 11% in June?3
MESOBLAST LIMITED ADR Aktie jetzt für 0€ handeln
12.06.MESOBLAST LTD - 6-K, Report of foreign issuer-
12.06.Mesoblast Moves Closer To FDA Approvals For Heart And Immune Disorder Treatments3
19.05.Dr Boreham's Crucible: Can this biotech emerge from Mesoblast's shadow and ride 'stem cells 2.0'?10
16.05.HotCopper Highlights Week 20: Mesoblast FDA miss; Larvotto posts tungsten, Melbana & More20
15.05.Mesoblast Secures FDA Orphan-Drug Approval For Ryoncil5
15.05.Mesoblast Limited: FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil317NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years...
► Artikel lesen
15.05.The market shrugged at Mesoblast's latest FDA win. Is it just another Droneshield?60
15.05.Thursday's HotCopper trends: Mesoblast's FDA tick, Anson's green light | May 15, 20252
30.04.Mesoblast Limited: Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025144NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided highlights of its recent...
► Artikel lesen
29.04.MESOBLAST LTD - 6-K, Report of foreign issuer3
29.04.Mesoblast Limited: Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board2
17.04.Mesoblast Limited: Mesoblast Extends Payer Coverage For Ryoncil to Over 100 Million US Lives254NEW YORK, April 16, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has continued to expand...
► Artikel lesen
15.04.MESOBLAST LTD - 6-K, Report of foreign issuer-
07.04.Top broker says Mesoblast shares can rocket 100%3
04.04.Hot Stocks: Domain Holdings, Southern Cross Electrical, Orthocell, Mesoblast2
04.04.HotCopper Highlights for Week 14 - Mesoblast, Cettire, Neurizon & more!2
04.04.Friday's HotCopper Trends: Mesoblast dodges tariffs, Orthocell's FDA tick | April 4, 20251
Weiter >>
82 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1